SCHEMBL7702556

SCHEMBL7702556

COC(=O)C(CNC(=O)CO/N=C/c1ccc(C(=N)N)cc1)NS(=O)(=O)c1cccc(C)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ F2 P00734 8/20 0.39
▸ GAA P10253 1/20 0.39
▸ TMPRSS6 Q8IU80 4/20 0.38
▸ ITGB3 P05106 2/20 0.38
▸ ITGA2B P08514 2/20 0.38
▸ PLAU P00749 2/20 0.37
▸ HPN P05981 2/20 0.37
▸ F10 P00742 1/20 0.37
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7702564 1.00 MAPT (0.41) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7697141 0.93 ITGB3 (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7697136 0.93 ITGB3 (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7698698 0.92 ITGB3 (0.40) F2TMPRSS6ITGB3ITGA2BPLAU
SCHEMBL7698702 0.92 ITGB3 (0.40) F2TMPRSS6ITGB3ITGA2BPLAU
SCHEMBL7697072 0.87 F2 (0.41) HPGDF2TMPRSS6ITGB3ITGA2B
SCHEMBL7704937 0.86 LMNA (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7704935 0.86 LMNA (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7702507 0.85 ITGB3 (0.47) F2TMPRSS6ITGB3ITGA2B
SCHEMBL7702513 0.85 ITGB3 (0.47) F2TMPRSS6ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6348504-B1 COMPOUNDS WITH AMIDINE OR GUANIDINE GROUPS AND CARBOXY OR ESTER GROUPS THROMBOLYTICS AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS. DUPONT PHARMACEUTICALS COMPANY 2002-02-19 — — US disclosed
Send feedback